keyword
MENU ▼
Read by QxMD icon Read
search

Modified vaccinia virus ankara

keyword
https://www.readbyqxmd.com/read/27920181/chikungunya-virus-vaccines-viral-vector-based-approaches
#1
Katrin Ramsauer, Frédéric Tangy
In 2013, a major chikungunya virus (CHIKV) epidemic reached the Americas. In the past 2 years, >1.7 million people have been infected. In light of the current epidemic, with millions of people in North and South America at risk, efforts to rapidly develop effective vaccines have increased. Here, we focus on CHIKV vaccines that use viral-vector technologies. This group of vaccine candidates shares an ability to potently induce humoral and cellular immune responses by use of highly attenuated and safe vaccine backbones...
December 15, 2016: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/27876199/comparison-of-homologous-and-heterologous-prime-boost-immunizations-combining-mva-vectored-and-plant-derived-vp2-as-a-strategy-against-ibdv
#2
Matías Richetta, Evangelina Gómez, María Soledad Lucero, Silvina Chimeno Zoth, María José Gravisaco, Gabriela Calamante, Analía Berinstein
Different immunogens such as subunit, DNA or live viral-vectored vaccines against Infectious Bursal Disease virus (IBDV) have been evaluated in the last years. However, the heterologous prime-boost approach using recombinant modified vaccinia Ankara virus (rMVA), which has shown promising results in both mammals and chickens, has not been tried against this pathogen yet. IBD is a highly contagious and immunosuppressive disease of poultry that affects mainly young chicks. It is caused by IBDV, a double-stranded RNA virus carrying its main antigenic epitopes on the capsid protein VP2...
November 18, 2016: Vaccine
https://www.readbyqxmd.com/read/27830736/viral-vector-vaccines-expressing-nucleoprotein-and-phosphoprotein-genes-of-avian-bornaviruses-ameliorate-homologous-challenge-infections-in-cockatiels-and-common-canaries
#3
Marita Olbert, Angela Römer-Oberdörfer, Christiane Herden, Sara Malberg, Solveig Runge, Peter Staeheli, Dennis Rubbenstroth
Avian bornaviruses are causative agents of proventricular dilatation disease (PDD), an often fatal disease of parrots and related species (order Psittaciformes) which is widely distributed in captive psittacine populations and may affect endangered species. Here, we established a vaccination strategy employing two different well described viral vectors, namely recombinant Newcastle disease virus (NDV) and modified vaccinia virus Ankara (MVA) that were engineered to express the phosphoprotein and nucleoprotein genes of two avian bornaviruses, parrot bornavirus 4 (PaBV-4) and canary bornavirus 2 (CnBV-2)...
November 10, 2016: Scientific Reports
https://www.readbyqxmd.com/read/27817963/a-mva-construct-expressing-a-secretable-form-of-the-dengue-virus-3-envelope-protein-protects-immunized-mice-from-dengue-induced-encephalitis
#4
Bárbara R Quinan, Alice Freitas Versiani, Flávio G da Fonseca
Dengue is no longer restricted to tropical developing countries, but is now a major global public health problem. Despite the recent license approval of the CYD-TDV vaccine in some countries, efforts to develop a more efficient vaccine against Dengue virus (DENV) continue. Herein, we evaluate the immunogenicity and level of protection of two potential vaccines against DENV based on recombinant modified vaccinia virus Ankara (rMVA). The vaccine addressing the Envelope protein from DENV serotype 3 to the endoplasmic reticulum elicited neutralizing antibodies titers which correlate with protection, and also confers protection upon challenge in a mouse model...
December 7, 2016: Vaccine
https://www.readbyqxmd.com/read/27809679/induction-of-both-local-immune-response-in-mice-and-protection-in-a-rabbit-model-by-intranasal-immunization-with-modified-vaccinia-ankara-virus-expressing-a-secreted-form-of-bovine-herpesvirus-1-glycoprotein-d
#5
María Paula Del Medico Zajac, Flavia Adriana Zanetti, María Soledad Esusy, Carlos Rodolfo Federico, Osvaldo Zabal, Alejandro Rafael Valera, Gabriela Calamante
In this study, we evaluated the immunogenicity and efficacy of mucosal delivery of a recombinant modified vaccinia Ankara virus (MVA) expressing the secreted version of bovine herpesvirus type 1 (BoHV-1) glycoprotein D (MVA-gDs) without addition of adjuvant in two animal models. First, we demonstrated the capability of MVA-gDs of inducing both local and systemic anti-gD humoral immune response after intranasal immunization of mice. Then, we confirmed that two doses of MVA-gDs administered intranasally to rabbits induced systemic anti-gD antibodies and conferred protection against BoHV-1 challenge...
November 3, 2016: Viral Immunology
https://www.readbyqxmd.com/read/27760761/mva-vaccine-encoding-cmv-antigens-safely-induces-durable-expansion-of-cmv-specific-t-cells-in-healthy-adults
#6
Corinna La Rosa, Jeff Longmate, Joy Martinez, Qiao Zhou, Teodora I Kaltcheva, Weimin Tsai, Jennifer Drake, Mary Carroll, Felix Wussow, Flavia Chiuppesi, Nicola Hardwick, Sanjeet Dadwal, Ibrahim Aldoss, Ryotaro Nakamura, John A Zaia, Don J Diamond
Attenuated poxvirus Modified vaccinia Ankara (MVA) is a useful viral-based vaccine for clinical investigation, because of its excellent safety profile and property of inducing potent immune responses against recombinant (r) antigens. We developed Triplex by constructing an rMVA encoding three immunodominant CMV antigens which stimulates a host anti-viral response: UL83 (pp65), UL123 (IE1-exon4), and UL122 (IE2-exon5). We completed the first clinical evaluation of the Triplex vaccine in 24 healthy adults, with or without immunity to CMV and vaccinia virus (previous DryVax smallpox vaccination)...
October 19, 2016: Blood
https://www.readbyqxmd.com/read/27741426/non-plaque-forming-virions-of-modified-vaccinia-virus-ankara-express-viral-genes
#7
Anna-Theresa Lülf, Astrid Freudenstein, Lisa Marr, Gerd Sutter, Asisa Volz
In cell culture infections with vaccinia virus the number of counted virus particles is substantially higher than the number of plaques obtained by titration. We found that standard vaccine preparations of recombinant Modified Vaccinia virus Ankara produce only about 20-30% plaque-forming virions in fully permissive cell cultures. To evaluate the biological activity of the non-plaque-forming particles, we generated recombinant viruses expressing fluorescent reporter proteins under transcriptional control of specific viral early and late promoters...
October 11, 2016: Virology
https://www.readbyqxmd.com/read/27687310/vectorized-gene-therapy-of-liver-tumors-proof-of-concept-of-tg4023-mva-fcu1-in-combination-with-flucytosine
#8
F Husseini, J-P Delord, C Fournel-Federico, J Guitton, P Erbs, M Homerin, C Halluard, C Jemming, C Orange, J-M Limacher, J-E Kurtz
BACKGROUND: TG4023 is a modified vaccinia virus Ankara (MVA) containing the yeast-originated transgene FCU1, expressing cytosine deaminase and uracil phosphoribosyltransferase enzymes that transform the prodrug flucytosine (5-FC) into cytotoxic 5-fluorouracil (5-FU) and 5-fluorouridine-5'-monophosphate (5-FUMP), respectively. This first-in-human study aimed to assess the maximum tolerated dose (MTD) of intra-tumoral (IT) TG4023 and the safety, feasibility, and proof-of-concept (PoC) of TG4023/5-FC combination to deliver high 5-FU concentrations in tumors...
September 29, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/27683750/high-doses-of-gm-csf-inhibit-antibody-responses-in-rectal-secretions-and-diminish-modified-vaccinia-ankara-simian-immunodeficiency-virus-vaccine-protection-in-trim5%C3%AE-restrictive-macaques
#9
Sunil Kannanganat, Linda S Wyatt, Sailaja Gangadhara, Venkatesarlu Chamcha, Lynette S Chea, Pamela A Kozlowski, Celia C LaBranche, Lakshmi Chennareddi, Benton Lawson, Pradeep B J Reddy, Tiffany M Styles, Thomas H Vanderford, David C Montefiori, Bernard Moss, Harriet L Robinson, Rama Rao Amara
We tested, in rhesus macaques, the effects of a 500-fold range of an admixed recombinant modified vaccinia Ankara (MVA) expressing rhesus GM-CSF (MVA/GM-CSF) on the immunogenicity and protection elicited by an MVA/SIV macaque 239 vaccine. High doses of MVA/GM-CSF did not affect the levels of systemic envelope (Env)-specific Ab, but it did decrease the expression of the gut-homing receptor α4β7 on plasmacytoid dendritic cells (p < 0.01) and the magnitudes of Env-specific IgA (p = 0.01) and IgG (p < 0...
November 1, 2016: Journal of Immunology: Official Journal of the American Association of Immunologists
https://www.readbyqxmd.com/read/27650872/infectivity-of-attenuated-poxvirus-vaccine-vectors-and-immunogenicity-of-a-raccoonpox-vectored-rabies-vaccine-in-the-brazilian-free-tailed-bat-tadarida-brasiliensis
#10
Ben R Stading, Jorge E Osorio, Andres Velasco-Villa, Michael Smotherman, Brock Kingstad-Bakke, Tonie E Rocke
Bats (Order Chiroptera) are an abundant group of mammals with tremendous ecological value as insectivores and plant dispersers, but their role as reservoirs of zoonotic diseases has received more attention in the last decade. With the goal of managing disease in free-ranging bats, we tested modified vaccinia Ankara (MVA) and raccoon poxvirus (RCN) as potential vaccine vectors in the Brazilian Free-tailed bat (Tadarida brasiliensis), using biophotonic in vivo imaging and immunogenicity studies. Animals were administered recombinant poxviral vectors expressing the luciferase gene (MVA-luc, RCN-luc) through oronasal (ON) or intramuscular (IM) routes and subsequently monitored for bioluminescent signal indicative of viral infection...
October 17, 2016: Vaccine
https://www.readbyqxmd.com/read/27617268/broad-hiv-1-inhibition-in-vitro-by-vaccine-elicited-cd8-t-cells-in-african-adults
#11
Gaudensia Mutua, Bashir Farah, Robert Langat, Jackton Indangasi, Simon Ogola, Brian Onsembe, Jakub T Kopycinski, Peter Hayes, Nicola J Borthwick, Ambreen Ashraf, Len Dally, Burc Barin, Annika Tillander, Jill Gilmour, Jan De Bont, Alison Crook, Drew Hannaman, Josephine H Cox, Omu Anzala, Patricia E Fast, Marie Reilly, Kundai Chinyenze, Walter Jaoko, Tomáš Hanke, The Hiv-Core 004 Study Group
We are developing a pan-clade HIV-1 T-cell vaccine HIVconsv, which could complement Env vaccines for prophylaxis and be a key to HIV cure. Our strategy focuses vaccine-elicited effector T-cells on functionally and structurally conserved regions (not full-length proteins and not only epitopes) of the HIV-1 proteome, which are common to most global variants and which, if mutated, cause a replicative fitness loss. Our first clinical trial in low risk HIV-1-negative adults in Oxford demonstrated the principle that naturally mostly subdominant epitopes, when taken out of the context of full-length proteins/virus and delivered by potent regimens involving combinations of simian adenovirus and poxvirus modified vaccinia virus Ankara, can induce robust CD8(+) T cells of broad specificities and functions capable of inhibiting in vitro HIV-1 replication...
2016: Molecular Therapy. Methods & Clinical Development
https://www.readbyqxmd.com/read/27581985/increased-protein-degradation-improves-influenza-virus-nucleoprotein-specific-cd8-t-cell-activation-in-vitro-but-not-in-c57bl-6-mice
#12
Arwen F Altenburg, Carolien E van de Sandt, Stella E van Trierum, Heidi L M De Gruyter, Peter R W A van Run, Ron A M Fouchier, Kenny Roose, Xavier Saelens, Asisa Volz, Gerd Sutter, Rory D de Vries, Guus F Rimmelzwaan
: Due to antigenic drift of influenza viruses, seasonal influenza vaccines need to be updated annually. These vaccines are based on predictions of strains likely to circulate in the next season. However, vaccine efficacy is greatly reduced in the case of a mismatch between circulating and vaccine strains. Furthermore, novel antigenically distinct influenza viruses are introduced into the human population from animal reservoirs occasionally and may cause pandemic outbreaks. To dampen the impact of seasonal and pandemic influenza, vaccines that induce broadly protective and long-lasting immunity are preferred...
November 15, 2016: Journal of Virology
https://www.readbyqxmd.com/read/27537523/anti-apoptotic-bcl-xl-but-not-mcl-1-contributes-to-protection-against-virus-induced-apoptosis
#13
Michaela Ohmer, Arnim Weber, Gerd Sutter, Katrin Ehrhardt, Albert Zimmermann, Georg Häcker
Infection of mammalian cells with viruses often induces apoptosis. How the recognition of viruses leads to apoptosis of the infected cell and which host cell factors regulate this cell death is incompletely understood. In this study, we focussed on two major anti-apoptotic proteins of the host cell, whose abundance and activity are important for cell survival, the Bcl-2-like proteins Mcl-1 and Bcl-XL. During infection of epithelial cells and fibroblasts with modified vaccinia virus Ankara (MVA), Mcl-1 protein levels dropped but the MVA Bcl-2-like protein F1L could replace Mcl-1 functionally; a similar activity was found in vaccinia virus (VACV)-infected cells...
August 18, 2016: Cell Death & Disease
https://www.readbyqxmd.com/read/27490575/highly-immunogenic-virally-vectored-t-cell-vaccines-cannot-overcome-subversion-of-the-t-cell-response-by-hcv-during-chronic-infection
#14
Leo Swadling, John Halliday, Christabel Kelly, Anthony Brown, Stefania Capone, M Azim Ansari, David Bonsall, Rachel Richardson, Felicity Hartnell, Jane Collier, Virginia Ammendola, Mariarosaria Del Sorbo, Annette Von Delft, Cinzia Traboni, Adrian V S Hill, Stefano Colloca, Alfredo Nicosia, Riccardo Cortese, Paul Klenerman, Antonella Folgori, Eleanor Barnes
An effective therapeutic vaccine for the treatment of chronic hepatitis C virus (HCV) infection, as an adjunct to newly developed directly-acting antivirals (DAA), or for the prevention of reinfection, would significantly reduce the global burden of disease associated with chronic HCV infection. A recombinant chimpanzee adenoviral (ChAd3) vector and a modified vaccinia Ankara (MVA), encoding the non-structural proteins of HCV (NSmut), used in a heterologous prime/boost regimen induced multi-specific, high-magnitude, durable HCV-specific CD4+ and CD8+ T-cell responses in healthy volunteers, and was more immunogenic than a heterologous Ad regimen...
August 2, 2016: Vaccines
https://www.readbyqxmd.com/read/27466414/virus-like-particles-displaying-trimeric-simian-immunodeficiency-virus-siv-envelope-gp160-enhance-the-breadth-of-dna-modified-vaccinia-virus-ankara-siv-vaccine-induced-antibody-responses-in-rhesus-macaques
#15
Smita S Iyer, Sailaja Gangadhara, Blandine Victor, Xiaoying Shen, Xuemin Chen, Rafiq Nabi, Sudhir P Kasturi, Michael J Sabula, Celia C Labranche, Pradeep B J Reddy, Georgia D Tomaras, David C Montefiori, Bernard Moss, Paul Spearman, Bali Pulendran, Pamela A Kozlowski, Rama Rao Amara
UNLABELLED: The encouraging results of the RV144 vaccine trial have spurred interest in poxvirus prime-protein boost human immunodeficiency virus (HIV) vaccine modalities as a strategy to induce protective immunity. Because vaccine-induced protective immunity is critically determined by HIV envelope (Env) conformation, significant efforts are directed toward generating soluble trimeric Env immunogens that assume native structures. Using the simian immunodeficiency virus (SIV)-macaque model, we tested the immunogenicity and efficacy of sequential immunizations with DNA (D), modified vaccinia virus Ankara (MVA) (M), and protein immunogens, all expressing virus-like particles (VLPs) displaying membrane-anchored trimeric Env...
October 1, 2016: Journal of Virology
https://www.readbyqxmd.com/read/27427967/hiv-1-subtype-c-mosaic-gag-expressed-by-bcg-and-mva-elicits-persistent-effector-t-cell-responses-in-a-prime-boost-regimen-in-mice
#16
Tsungai Ivai Jongwe, Ros Chapman, Nicola Douglass, Shivan Chetty, Gerald Chege, Anna-Lise Williamson
Over 90% of HIV/AIDS positive individuals in sub-Saharan Africa are infected with highly heterogeneous HIV-1 subtype C (HIV-1C) viruses. One of the best ways to reduce the burden of this disease is the development of an affordable and effective prophylactic vaccine. Mosaic immunogens are computationally designed to overcome the hurdle of HIV diversity by maximizing the expression of potential T cell epitopes. Mycobacterium bovis BCG ΔpanCD auxotroph and modified vaccinia Ankara (MVA) vaccines expressing HIV-1C mosaic Gag (GagM) were tested in a prime-boost regimen to demonstrate immunogenicity in a mouse study...
2016: PloS One
https://www.readbyqxmd.com/read/27416077/t-and-b-cell-responses-to-multivalent-prime-boost-dna-and-viral-vectors-vaccine-combinations-against-hepatitis-c-virus-in-non-human-primates
#17
C S Rollier, E J Verschoor, B E Verstrepen, J A R Drexhage, G Paranhos-Baccala, P Liljeström, G Sutter, L Arribillaga, J J Lasarte, B Bartosch, F-L Cosset, G Inchauspe, J L Heeney
Immune responses against multiple epitopes are required for the prevention of Hepatitis C Virus infection, and the progression to Phase I trials of candidates may be guided by comparative immunogenicity studies in non-human primates. Four vectors, DNA, SFV, human serotype 5 adenovirus (HuAd5) and Modified Vaccinia Ankara poxvirus (MVA), all expressing HCV Core, E1, E2 and NS3, were combined in three prime-boost regimen, and their ability to elicit immune responses against HCV antigens in rhesus macaques was explored and compared...
July 14, 2016: Gene Therapy
https://www.readbyqxmd.com/read/27357167/long-term-safety-of-replication-defective-smallpox-vaccine-mva-bn-in-atopic-eczema-and-allergic-rhinitis
#18
U Darsow, M Sbornik, S Rombold, K Katzer, F von Sonnenburg, H Behrendt, J Ring
BACKGROUND: Availability of a safe smallpox vaccine may be necessary under certain circumstances. Use of the old life virus vaccine was associated with serious adverse events, particularly in the setting of atopic eczema (AE) and immunodeficiency. Modified virus Ankara (MVA)-BN, a highly attenuated strain of vaccinia virus, was developed for vaccination with improved safety profile. METHODS: A phase 1 study was conducted in 60 subjects without history of smallpox vaccination to gain experience with smallpox vaccination using this strain in healthy and atopic subjects...
November 2016: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/27327616/a-randomized-double-blind-placebo-controlled-phase-ii-trial-investigating-the-safety-and-immunogenicity-of-modified-vaccinia-ankara-smallpox-vaccine-mva-bn%C3%A2-in-56-80-year-old-subjects
#19
Richard N Greenberg, Christine M Hay, Jack T Stapleton, Thomas C Marbury, Eva Wagner, Eva Kreitmeir, Siegfried Röesch, Alfred von Krempelhuber, Philip Young, Richard Nichols, Thomas P Meyer, Darja Schmidt, Josef Weigl, Garth Virgin, Nathaly Arndtz-Wiedemann, Paul Chaplin
BACKGROUND: Modified Vaccinia Ankara MVA-BN® is a live, highly attenuated, viral vaccine under advanced development as a non-replicating smallpox vaccine. In this Phase II trial, the safety and immunogenicity of Modified Vaccinia Ankara MVA-BN® (MVA) was assessed in a 56-80 years old population. METHODS: MVA with a virus titer of 1 x 108 TCID50/dose was administered via subcutaneous injection to 56-80 year old vaccinia-experienced subjects (N = 120). Subjects received either two injections of MVA (MM group) or one injection of Placebo and one injection of MVA (PM group) four weeks apart...
2016: PloS One
https://www.readbyqxmd.com/read/27272940/protective-effects-of-a-modified-vaccinia-ankara-based-vaccine-candidate-against-crimean-congo-haemorrhagic-fever-virus-require-both-cellular-and-humoral-responses
#20
Stuart D Dowall, Victoria A Graham, Emma Rayner, Laura Hunter, Robert Watson, Irene Taylor, Antony Rule, Miles W Carroll, Roger Hewson
Crimean-Congo Haemorrhagic Fever (CCHF) is a severe tick-borne disease, endemic in many countries in Africa, the Middle East, Eastern Europe and Asia. There is no approved vaccine currently available against CCHF. The most promising candidate, which has previously been shown to confer protection in the small animal model, is a modified Vaccinia Ankara virus vector expressing the CCHF viral glycoprotein (MVA-GP). It has been shown that MVA-GP induces both humoral and cellular immunogenicity. In the present study, sera and T-lymphocytes were passively and adoptively transferred into recipient mice prior to challenge with CCHF virus...
2016: PloS One
keyword
keyword
11297
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"